Medibact GuidesShop at Medibact

Stacking Module

VIP Stacking Module

VIP (Vasoactive Intestinal Peptide) has a well-established physiological role — it is a real signalling molecule with characterised receptors — but almost none of that translates into evidence for administering it. Its stacking discussion sits in gut and immune contexts, and its most important practical fact is its route and its vasoactivity.

VIP Guide at MedibactVIP calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking VIP

  • VIP is an endogenous neuropeptide with established physiological functions including vasodilation and smooth-muscle relaxation. Its name is descriptive of a real effect, which matters for safety.
  • Its vasoactivity is the specific practical consideration — flushing and blood-pressure effects are reported, which is relevant when combining it with anything else that has cardiovascular activity.
  • Reported administration is predominantly intranasal in the protocols it appears in, not injected.
  • No controlled trial has studied VIP combined with anything; evidence for administered VIP is thin despite the molecule being well characterised.

Combinations in detail

VIP + BPC-157

Vasoactive neuropeptide + repair peptide
Why it is proposed
Reported together in gut and tissue-repair contexts through unrelated mechanisms — VIP receptor signaling versus BPC-157's repair literature.
What is reported in practice
VIP reported intranasally, BPC-157 injected or oral in gut contexts.
Cautions specific to this combination
VIP's vasoactive effects are the practical concern. No combination data.

VIP + KPV

Vasoactive neuropeptide + anti-inflammatory tripeptide
Why it is proposed
Both discussed in gut and inflammatory contexts via different mechanisms.
What is reported in practice
Separate compounds; both discussed with non-injected routes in gut contexts.
Cautions specific to this combination
Gastrointestinal conditions serious enough to motivate this combination warrant clinical assessment.

VIP + Thymosin Alpha-1

Vasoactive neuropeptide + immune modulator
Why it is proposed
Reported for immune modulation in chronic-inflammatory discussion; unrelated mechanisms.
What is reported in practice
Separate compounds.
Cautions specific to this combination
Thymosin Alpha-1 is the better-evidenced half; no combination data.

What to avoid, and why

  • Ignoring vasoactivity when combining with any compound that affects blood pressure — PT-141 and Melanotan II both do.
  • Reading VIP's established physiological role as evidence for administering it; those are separate claims.
  • Assuming injection matches the reported route, which is predominantly intranasal.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.